Focus on design tools, plasmids and vectors, Cas9 and g-RNA, delivery system products



DUBLIN, September 21, 2021 / PRNewswire / – The “CRISPR market – Forecasts from 2021 to 2026” report was added to offer.

The global CRISPR market is valued at US $ 0.979 billion for the year 2019 and is expected to grow at a CAGR of 35.96% to reach a market size of 8.406 billion US dollars by 2026.

The global CRISPR market is growing with major investments from developed countries. The global genome editing market is experiencing a high growth rate after the discovery of a cutting edge tool – “CRISPR”, short for “Clustered Regularly Interspaced Short Palindromic Repeats”. CRISPR-based tools are increasingly adopted by companies around the world for new developments in areas such as genome editing, genetic engineering, biotechnology, pharmacy and agriculture.

Growing need for drug research, risk of birth defects, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward. The increase in the geriatric population, changes in lifestyle and investments in advanced research technologies are also increasing the size of the market. Genetic diseases are more and more common, genetic diseases are more and more prevalent and people are more and more aware of gene therapies, which leads to further development of the market.

Wide Possible Applications to Drive Market Growth

CRISPR technology is widely used for a variety of applications. Genome editing, also known as genetic engineering, is a technique for modifying an organism’s genome using molecular machines and nucleases designed to perform deletions, insertions, or substitutions in DNA. of a living creature. A gene library is a collection of cloned deoxyribonucleic acid (DNA) fragments that contain information about the functionality of a gene. CRISPR plasmids are widely used for gene disruption and direct repair of homologous genes.

Pairwise, a CRISPR-focused food company, received USDA clearance in August 2020 for its genetically modified form of Brassica juncea, also known as mustard greens. Pairwise has learned from the USDA that their innovative approach to a leafy green that hasn’t been on many menus due to a strong smell and unpleasant taste has been allowed to continue. Pairwise wants to produce a healthy and tasty alternative to kale and Brussels germ using CRISPR technology to engineer modifications.

PerkinElmer and Qiagen are the latest medical technologies to enter the rapidly developing CRISPR industry, with technology intended to help gene editing to cure cancer, hemophilia, sickle cell anemia and other diseases. Qiagen introduced new CRISPR products to help researchers better understand the gene-editing effect of their work, while PerkinElmer acquired SIRION Biotech, a German viral vector gene delivery company, to expand its box. CRISPR gene editing tools in June 2021.

Rapid increase in genetic disorders to expand market demand

The increase in genetic disorders is also easing the market demand. According to the Global Alliance for Genomics and Health (GA4GH), more than 60 million individuals will have had their genome sequenced in hospitals by 2025, but the mechanisms for processing data generated by genome sequencing are still in its infancy.

As the United States National Center for Biotechnology Information reports, although genetic diseases are individually rare, they make up about 80% of rare diseases, which number in the thousands. The large amount of rare diseases means that one in seventeen people are affected.

Capsida Biotherapeutics, a US-based startup, was formed in 2019 to use gene therapy to treat serious illnesses. The firm has just unveiled an important development which could hasten its ambitions. The company announced a collaboration with CRISPR Therapeutics, a pioneer in gene medicine, in June 2021 to co-develop therapies for two rare diseases with no known cure: at Lou Gehrig Amyotrophic lateral sclerosis or disease (ALS) and Friedreich’s ataxia.

Intensify research and development to offer opportunities to market players

There is a lot of research and development going on in the market that is expected to increase the opportunities due to the slanting trends in the market. As reported by the National Cancer Institute in the United States, Since the discovery that DNA mutations cause cancer, scientists have been looking for a simple approach to reverse these changes by modifying DNA. Several gene editing techniques have been developed over the years, but none has really met the criteria for fast, simple and inexpensive technology.

Cancer researchers jumped at the possibility of using CRISPR as soon as it hit the shelves and freezers of labs around the world. CRISPR is now being tested on cancer patients rather than in lab boxes. Researchers tested a cancer treatment involving immune cells that were modified by CRISPR to better hunt and attack cancer in a small study.

Main topics covered:

1. Introduction
1.1. Market definition
1.2. Market segmentation

2. Research methodology
2.1. Research data
2.2. Hypotheses

3. Executive summary
3.1. Research Highlights

4. Market dynamics
4.1. Market factors
4.2. Market constraints
4.3. Porters Five Forces Analysis
4.4. Industry value chain analysis

5. CRISPR market analysis, by product
5.1. introduction
5.2. Design tools
5.3. Plasmid and vector
5.4. Cas9 and gRNA
5.5. Delivery system products

6. CRISPR Market Analysis, By Application
6.1. introduction
6.2. Genome editing
6.3. Genetic engineering
6.4. GMOs and crops
6.5. Human stem cells
6.6. Others

7. CRISPR market analysis, by geography

8. Competitive intelligence
8.1. Benchmarking and competitive analysis
8.2. Recent investment and transactions
8.3. Strategies of key players

9. Company profiles

  • Addgene
  • CRISPR Therapeutics
  • Editas Medicine
  • Egenèse, Inc.
  • GE Healthcare
  • GenScript biotechnology company
  • Horizon PLC Discovery Group
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links


About Author

Leave A Reply